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ANALYSIS OF DRUG-PROTEIN BINDING BY ULTRAFAST
AFFINITY CHROMATOGRAPHY USING IMMOBILIZED HUMAN
SERUM ALBUMIN
Rangan Mallik, Michelle J. Yoo, Chad J. Briscoe, and David S. Hage*
Chemistry Department, University of Nebraska, Lincoln, NE 68588-0304 (USA)

Abstract
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Human serum albumin (HSA) was explored for use as a stationary phase and ligand in affinity
microcolumns for the ultrafast extraction of free drug fractions and the use of this information for
the analysis of drug-protein binding. Warfarin, imipramine, and ibuprofen were used as model
analytes in this study. It was found that greater than 95% extraction of all these drugs could be
achieved in as little as 250 ms on HSA microcolumns. The retained drug fraction was then eluted
from the same column under isocratic conditions, giving elution in less than 40 s when working at
4.5 mL/min. The chromatographic behavior of this system gave a good fit with that predicted by
computer simulations based on a reversible, saturable model for the binding of an injected drug with
immobilized HSA. The free fractions measured by this method were found to be comparable to those
determined by ultrafiltration, and equilibrium constants estimated by this approach gave good
agreement with literature values. Advantages of this method include its speed and the relatively low
cost of microcolumns that contain HSA. The ability of HSA to bind many types of drugs also creates
the possibility of using the same affinity microcolumn to study and measure the free fractions for a
variety of pharmaceutical agents. These properties make this technique appealing for use in drug
binding studies and in the high-throughput screening of new drug candidates.

Keywords
Affinity chromatography; Affinity microcolumns; Human serum albumin; Drug-protein binding;
High-throughput screening; Warfarin; Ibuprofen; Imipramine
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1. Introduction
Many drugs are non-covalently bound to serum proteins or other binding agents in the
circulation [1,2]. This feature makes the determination of free drug fractions and studies of
binding by drugs with serum proteins a topic of great interest in clinical and pharmaceutical
research [3]. Several previous methods have been developed for the measurement of drugprotein binding and free drug fractions [5–16]. Two reference methods for such work are
equilibrium dialysis and ultrafiltration [1,4]. However, these techniques often involve long
analysis time (e.g., equilibrium dialysis) or suffer from errors due to nonspecific interactions
between the drugs or proteins and components of the analysis system (e.g., dialysis or filtration

*Author for correspondence: Phone, 402-472-2744; FAX, 402-472-9402; dhage@unlserve.unl.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.

Mallik et al.

Page 2

NIH-PA Author Manuscript

membranes). Other methods that have been used for drug-protein binding studies include
nuclear magnetic resonance spectroscopy (NMR) [5–8], UV/Vis spectroscopy [9], circular
dichroism [10], surface plasmon resonance (SPR) [10–15]. However, these methods also have
limitations, such as potential interferences from the sample, the ability to work with only certain
types of analytes, the need for analytes with suitably high concentrations or levels of binding
for detection, and/or the requirement for relatively specialized equipment.
Additional methods for examining drug-protein binding include HPLC and CE methods that
employ proteins as stationary phases or buffer additives (see reviews in Refs. [17–19]). These
methods include numerous reports in which immobilized human serum albumin (HSA) has
been used in standard-size HPLC columns for thermodynamic studies of drug-protein binding
and for chiral separations [19–31]. This approach can be viewed as type of weak affinity
chromatography that is used to study interactions between drugs and proteins [32–34]. More
recently, affinity microcolumns that contain immobilized antibodies have been used for the
ultrafast extraction and determination of free drug fractions, giving results that show good
agreement with reference methods [35–37].
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This report will consider the use of a general binding agent such as HSA in affinity
microcolumns for the rapid extraction and measurement of free drug fractions. HSA is the most
abundant serum protein and is an important binding agent for a wide range of drugs and small
solutes in serum [17–19,21–23]. An advantage of using HSA in place of antibodies in affinity
microcolumns for the rapid extraction of free drug fractions is the lower association equilibrium
constants of drugs for HSA (103–105 M−1) vs. antibodies (106–1012 M−1) [17,18,38]. This
lower binding affinity should make it possible to use isocratic elution with HSA microcolumns
during the extraction and measurement of free drug fractions (see Figure 1). This feature should,
in term, eliminate the time-consuming elution and regeneration steps that are often needed with
immobilized antibody columns [38]. A second advantage of using HSA is the ability of this
protein to bind to many different drugs [17–19,21–23], thus providing an affinity microcolumn
that could be adapted for use with more than one analyte in free fraction measurements.
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The feasibility of using HSA microcolumns in ultrafast extraction and free fraction
measurements will be examined in this work by using warfarin, ibuprofen, and imipramine as
model drugs [27–30]. These drugs all have well-characterized interactions with HSA, with
R- and S-warfarin also having been used previously in the initial development of antibodybased microcolumns for the ultrafast extraction and determination of free drug fractions [36].
The creation of HSA microcolumns will be described in this report and the behavior of these
microcolumns will be compared with that predicted by computer simulations for the degree of
free drug extraction and retention by immobilized HSA. The use of such columns in measuring
free drug fractions and in examining drug-protein binding will then be considered. The results
of this work should provide important clues concerning the conditions that can be employed
in the use of HSA microcolumns for ultrafast extraction and in the extension of this method to
other drugs or small solutes.

2. Materials and methods
2.1 Reagents
The R-(+) and S-(−)-warfarin were donated by Du Pont Pharmaceuticals (Wilmington, DE,
USA). The S-(+)-ibuprofen was from Acros Organics (Morris Plains, NJ, USA). The HSA
(Cohn fraction V, essentially fatty acid free) and imipramine hydrochloride were from Sigma
(St. Louis, MO, USA). The Nucleosil Si-300 silica (7 μm particle diameter, 300 Å pore size)
and aminopropyl Nucleosil Si-300 used to make the SMCC silica (7 μm particle diameter, 300
Å pore size) were from Macherey Nagel (D ren, Germany). The succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate (SMCC) and reagents for the bicinchoninic acid
J Chromatogr A. Author manuscript; available in PMC 2011 April 23.
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(BCA) protein assay were from Pierce (Rockford, IL, USA). All aqueous solutions were
prepared using water from a Nanopure water system (Barnstead, Dubuque, IA, USA) and
filtered using Osmonics 0.22 μm nylon filters from Fisher (Pittsburgh, PA, USA).
2.2 Apparatus
The affinity microcolumns were packed using a LC-10 AT pump from Shimadzu (Columbia,
MD, USA) and a Rheodyne six port manual valve (Cotati, CA, USA) equipped with a 200
μL sample loop. The system used in the chromatographic studies consisted of a Shimadzu
LC-10 AD pump and a Shimadzu RF-535 fluorescence detector, with samples being injected
using a Rheodyne LabPro valve and 1.1 μL sample loop. Chromatographic data were collected
and processed using in-house programs written in LabView 5.1 (National Instruments, Austin,
TX, USA). The ultrafiltration studies were performed using a Sorvall RC 5B Plus centrifuge
with temperature control from DuPont (Wilmington, DE, USA).
2.3 Column preparation
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The stationary phase in these studies consisted of immobilized HSA on Nucleosil Si-300 silica
particles. The Schiff base immobilization technique (i.e., an amine-based coupling technique)
and the SMCC technique (i.e, a method which couples proteins through free sulfhydryl groups)
were performed according to the literature [39,40]. Control supports were prepared in the same
manner but with no HSA being added during the immobilization step. The protein contents of
the final HSA supports were determined in triplicate by a BCA assay using HSA as the standard
and the control support as the blank, giving 49 (± 6) mg HSA/g silica (± 1 S.D.) for the Schiff
base method and 46 (± 1) mg HSA/g silica for the SMCC method.
An HPLC pump was used to pack 4.5 × 2.1 mm i.d. columns when using the Schiff base method,
and similar 2.5 or 3.5 mm long columns for the SMCC method. A special column housing was
used to hold this small column, as described in Ref. [41]. These columns were packed according
to procedures given in Ref. [36] and gave a packing density for the supports of 0.49 g/mL. The
packing solution was pH 7.4, 0.067 M potassium phosphate buffer, and the packing pressure
was 2500 psi.
2.4 Chromatographic studies
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The mobile phase was pH 7.4, 0.067 M potassium phosphate buffer. All samples were prepared
in this buffer and allowed to incubate for at 25°C at least 15 min prior to injection. The relatively
fast association and dissociation kinetics that are typical of these drug-protein interactions [8,
24,28] made this period of time more than sufficient to reach equilibrium in the samples prior
to analysis. All injections made in this study were done in triplicate. In the initial work
conducted with HSA microcolumns prepared by the Schiff base method, the enantiomers of
warfarin were detected by monitoring their fluorescence emission at 445 nm when using an
excitation wavelength of 310 nm; the samples used in these studies contained 8.5–10.0 μM
R- or S-warfarin and 0.0 μM or 20.0 μM HSA (note: the sample concentrations used in this
particular study were chosen based on the detection limits of the given drugs and in keeping
with the goal of using the proposed method for screening drug-protein binding and obtaining
simple measurements of binding affinity with HSA). In later work using HSA microcolumns
prepared by the SMCC method, wavelengths utilized for the absorbance detection of warfarin,
imipramine, and ibuprofen were 310 nm, 251 nm, and 225 nm, respectively. The samples in
this second group of studies contained approximately 20.0 μM S-warfarin plus 0.0 μM or 25.0
μM HSA, or 40.0 μM S-ibuprofen or imipramine plus 0.0 μM or 45.0 μM HSA. All columns
were enclosed in water jackets for temperature control. All chromatographic work in this study
was performed at 25 (± 1) °C. The retention times and peak areas were measured by using
Peakfit 4.12 (Systat Software, San Jose, CA, USA). The residence time of a non-retained solute
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2.5 Ultrafiltration studies

NIH-PA Author Manuscript

Centricon centrifugal filters containing an Ultracel YM-3 membrane (3000 MW cut-off) were
purchased from Millipore (Billerica, MA, USA). All samples measured by ultrafiltration were
examined in triplicate. Before introduction of the sample, each of these filtration devices was
filled with 2 mL of pH 7.4, 0.067 M potassium phosphate buffer. The membrane was washed
by spinning the filtration device at 5000 × g until more than 1.8 mL of the pH 7.4 buffer had
passed into the filtrate vial, a process which took approximately 2 h. To remove the remaining
buffer, the device was inverted and spun at 1000 × g for about 1 min. Immediately after this
washing process, 1 mL portions of the desired drug solution or drug/protein sample were
introduced into three centrifugal filters and capped to avoid evaporation. These samples were
spun in the centrifugal filters at 7500 × g and 25 °C for 45 min. The filtrates were collected
and their contents were analyzed by HPLC. This analysis was conducted by making three 20
μL injections of each sample at 1.0 mL/min under isocratic conditions using pH 7.4, 0.067 M
potassium phosphate buffer as the mobile phase and a standard HSA column prepared in the
same method as described earlier [39]. The elution of these drugs was detected by using the
same conditions for fluorescence or absorbance measurements as described in Section 2.4. The
concentration of drug in each filtrate was determined by comparing the measured peak area
for the filtrate to that obtained under the same conditions for standards containing the desired
drug. In each case, the standards were pretreated by ultrafiltration in the same manner as the
samples to correct for any non-specific binding of the drug to the ultrafiltration membranes.
2.6 Chromatographic simulations
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Simulations of drug extraction and elution on HSA microcolumns were conducted using
programs written in Matlab R14SP3 (Mathworks, Nattick, MA, USA). These simulations were
based on a grid propagation algorithm and saturable binding with second-order association
kinetics, as used previously to examine the ultrafast extraction of analytes by immobilized
antibodies in affinity microcolumns [36], but with reversible binding between the analyte and
ligand now being present. The simulations were typically conducted with a column divided
into 50 slices of equal width, with no significant differences being noted when using up to 150
slices per column. The association equilibrium constants and association/dissociation rate
constants employed in these simulations were based on literature values for the binding of Rand S-warfarin with immobilized HSA under the same buffer and temperature conditions as
used in this report [42,43]. Other adjustable parameters (e.g., column size, amount of
immobilized ligand, and flow rate) were selected based on the experimental conditions
employed in this study.
It was assumed in these simulations that mass transfer of the analyte between the flowing
mobile phase and stagnant mobile phase (i.e., as based diffusion) was much faster than the
rates of analyte association and dissociation with the immobilized ligand. This assumption was
supported by previous kinetic studies of R- and S-warfarin on immobilized HSA columns
[43]. During the simulation, this situation was modeled by first allowing the analyte to partition
between the flowing mobile phase and stagnant mobile phase regions of each slice using a local
equilibrium model and a 1:1 volume ratio for these two regions (i.e., the approximate volume
ratio present for the support used in this report, based on data from the manufacturer).
Association and dissociation of the analyte with the immobilized ligand in contact with the
stagnant mobile phase region of each slice was then allowed to occur, as described by using
mass balance and differential equations for reversible second-order association and first-order
dissociation reactions. The moles of analyte in the mobile phase and stationary phase regions
of each slice and during each interval of time during the simulation were determined by using
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these equations and the ODE15S ordinary differential equation solving algorithm in MATLAB
[44,45]. Flow through the column was modeled by moving the analyte in the flowing mobile
phase region of one slice into the same region of the next slice after each iteration of the
simulation. The amount of analyte eluting from the last slice of the column was monitored and
used to generate the simulated chromatograms.

3. Results and discussion
3.1 Initial selection of conditions
The general scheme examined in this report for the measurement of free drug fractions is shown
in Figure 1. In this scheme, the injection of a mixture containing a drug and HSA (or other
binding protein) onto an HSA microcolumn and under appropriate flow rate conditions gives
a non-retained peak for a drug-protein complex, while the free drug fraction is extracted and
retained by the column. The result is a separation of the free and protein-bound drug fractions
in the sample. According to this scheme, the area of the peak due to the free drug fraction can
be measured and compared to injections for standards to determine the free drug concentration
in the original sample. If the time allowed for this extraction and separation is sufficiently
small, it should be possible with this approach to avoid any appreciable errors in this
measurement due to dissociation of drug-protein complexes in the sample as these complexes
pass through the column [36,39,46].

NIH-PA Author Manuscript

The approach shown in Figure 1 was initially evaluated by using R- and S-warfarin as model
analytes. It has been noted in previous modeling studies for the warfarin/HSA system that an
extraction time of less than a few hundred milliseconds is needed to avoid significant
dissociation of R- and S-warfarin from soluble HSA during the isolation of free fractions for
these drugs by antibody microcolumns [36]. Similar time scales for ultrafast affinity extraction
have been calculated and observed for other drugs and hormones [39,46]. Based on previous
equilibrium and rate constants reported for the binding and dissociation of R- and S-warfarin
with HSA [42,43], the same types of calculations were conducted in this current study. In a
worse-case scenario (e.g., a case with no re-association of drug released from proteins in the
sample and complete extraction of the released drugs) [36], less than 10–15% error was
predicted in the measured free fractions for R- and S-warfarin in the tested warfarin/HSA
mixtures when using an extraction time of approximately 300 ms or less. Similar column
residence times were used for the other drugs examined in this study. For example, an injection
flow rate of 4.5 mL/min on a 4.5 mm × 2.1 mm i.d. HSA microcolumn was determined
experimentally to give an effective extraction time and column residence time of approximately
250 ms for a non-retained solute in the HSA microcolumns.
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The HSA microcolumns prepared in this study were first tested for their ability to extract Rand S-warfarin in this desired time domain. The injected samples consisted of 1.1 μL injections
containing up to 8.5 μM S-warfarin or 10 μM R-warfarin. These sample conditions
corresponded to an amount of injected analyte that was less than 0.18% of the estimated column
binding capacity, or more than a 580-fold mol excess of HSA versus S- or R-warfarin. At all
flow rates used in this study (i.e., 0.5 to 5.0 mL/min), more than 95% extraction occurred for
both R- and S-warfarin in the absence of any soluble HSA. This result confirmed it was possible
to use HSA microcolumns (in this case, a 4.5 mm × 2.1 mm i.d. column) to quantitatively
remove these drugs from injected samples on the time scale of a few hundred milliseconds.
The next set of studies examined the ability of HSA microcolumns to separate the free and
protein-bound fractions of R- and S-warfarin in mixtures of these drugs with an excess of
soluble HSA. Figure 2 shows some representative chromatograms obtained for R-warfarin;
similar results were noted for S-warfarin. The peak in Figure 2(a) was obtained by injecting
only R-warfarin onto an HSA microcolumn. It was noted that essentially all of the R-warfarin
J Chromatogr A. Author manuscript; available in PMC 2011 April 23.
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was extracted and removed from the non-retained peak, which appeared at an elution time of
2–4 s on a control column. The retained R-warfarin was then later eluted from the HSA
microcolumn under the same mobile phase and flow rate conditions. This retained peak had a
maximum at approximately 15–17 s, with all the retained drug being eluted within 35–40 s.
Figure 2(b) shows the results when the same amount of R-warfarin was injected onto an HSA
microcolumn in a sample that now contained an excess of soluble HSA. In this case, a large
non-retained peak was noted at 2–5 s due to soluble HSA in the sample and the non-extracted
complex of R-warfarin with this HSA. The second, smaller peak that eluted later with a
maximum at 17–18 s represents R-warfarin that was extracted by the HSA microcolumn and
that presumably represented the free fraction of R-warfarin in the sample. Sufficient resolution
was obtained between the non-retained and retained peaks in this separation to allow the
extracted fraction of R-warfarin to be measured. Figure 2(c) shows a chromatogram obtained
when the same mixture of R-warfarin and soluble HSA was injected onto an inert control
column. In this case, only a non-retained peak was noted, indicating that neither R-warfarin
nor HSA, as well as the corresponding complex of R-warfarin with soluble HSA, had any
appreciable non-specific interactions with the support. Similar results were obtained for Swarfarin at the flow rates used in this study (e.g., see Section 3.4).
3.2 Simulations of free drug extraction and retention using HSA microcolumns
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The extraction and retention behavior noted experimentally for R- and S-warfarin on HSA
microcolumns were compared to theoretical chromatographic simulations of this system. These
simulations made use a reversible, saturable model for binding of the injected drugs with
immobilized HSA. The equilibrium and rate constants utilized in these simulations were based
on measured values obtained for immobilized HSA that had been prepared according to the
same general approach as employed in this current study [42,43]. The column size, amount of
immobilized HSA, sample content, and flow rates employed in these simulations were selected
based on the experimental conditions used in the previous section of this report.
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Good agreement was also noted in the relative shape and position of the retained peaks in the
experimental and simulated chromatograms, as can be seen by comparing the results for Rwarfarin in Figures 2 and 3(a). This observation indicated that a reversible, saturable model
for drug association and dissociation gave a reasonable description of the retention and elution
that was actually noted for R- and S-warfarin on the HSA microcolumns. The good fit of this
model to the experimental data further indicated that the broad nature of the retained peaks for
R- and S-warfarin was mainly related to the kinetics of dissociation and association for these
drugs with the immobilized HSA (i.e., stationary phase mass transfer) rather than to stagnant
mobile phase mass transfer under the conditions used in these experiments. However, sufficient
resolution was still obtained in this study between the peaks for the retained and non-retained
fractions of these analytes to make free drug fraction measurements possible with the HSA
microcolumns.

Figure 3(a) shows the simulation results for R-warfarin under the conditions used to obtain the
experimental data in Figure 2. A comparison of these results indicates there was agreement
between the experimental data and simulated chromatograms. Similar agreement between the
experimental and simulated data was noted for S-warfarin (data not shown). Based on these
simulations, it was confirmed that more than 95% extraction of the free drug fractions for Rand S-warfarin should have occurred at the flow rates used in this report with the HSA
microcolumns. It was also confirmed that the extracted and retained portion of these drugs
would later elute under isocratic conditions in the presence of the pH 7.4 application buffer.

Along with column size and flow rate, the amount of active ligand in an affinity microcolumn
is another factor that was found to be important in determining the final degree of resolution
J Chromatogr A. Author manuscript; available in PMC 2011 April 23.
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that is obtained between retained and non-retained drug fractions. The effect of varying this
parameter is illustrated in Figure 3(b). As the amount of active ligand (e.g., immobilized HSA)
was decreased in the simulations, there was a corresponding decrease in the peak elution time
for the retained drug. This shift resulted in lower resolution and greater overlap with the nonretained sample components. In addition, these results indicate that an increase in the amount
of active ligand within an affinity microcolumn would be expected to lead to higher retention
and resolution between the retained and non-retained fractions in a sample. Further studies are
now underway to improve the amount of active ligand within such columns as a means for
expanding the range of drugs that can be examined by this approach.
The data in Figure 3(b) demonstrate the need to have affinity microcolumns that are sufficiently
stable in their activity to avoid shifts in retention during the analysis of free drug fractions.
This was not a problem in this current study because the particular type of immobilized HSA
support that was employed has been shown in many previous reports to be quite stable over a
relatively long period of time (e.g., typically more than six months and over 500 sample
injections) [17,42,43,47]. The microcolumns employed in this report were used over a much
shorter period of time, which explains why significant shifts in the position of the retained drug
peaks were not noted experimentally. Even if such changes did occur, these shifts could have
been detected by making routine injections of control drug samples, with a new HSA
microcolumn then being placed into the system as needed.
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3.3 Analysis of free drug fractions
Based on results such as shown in Figure 2, it was possible to calculate the free fraction of Rwarfarin or S-warfarin in samples containing these drugs and soluble HSA. For example, this
was accomplished by dividing the retained peak area in Figure 2(b) (representing the free
fraction of R-warfarin) by the total peak area for the same drug in Figure 2(a) in the absence
of any soluble HSA. In this case, the chromatogram obtained for a mixture of R-warfarin and
HSA on the control column, as given in Figure 2(c), was also used to make a small correction
for any overlap that was present between the retained peak for R-warfarin in Figure 2(b) and
the non-retained peak for HSA plus the complex of R-warfarin with soluble HSA in the injected
samples.
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The effect of flow rate on this type of free fraction measurement was considered during the
optimization of this method. It is known from earlier work with antibody-based microcolumns
that using low flow rates for sample injection will allow for a maximum level of drug extraction,
but low flow rates also increase the amount of time over which the protein-bound form of an
analyte in a sample can dissociate. This situation is undesirable because it can lead to a positive
error in free fraction measurements [36,39,46]. This second effect is illustrated in Figure 4 for
ultrafast extraction on a 4.5 mm × 2.1 mm i.d. HSA microcolumn when using samples that
contained 8.5 μM S-warfarin and 20 μM HSA. The degree of extraction for S-warfarin in the
absence of soluble HSA was 95% at all of the flow rates in this plot, as discussed earlier. As
expected, the size of the apparent free fraction measured for S-warfarin increased as the
injection flow rate was decreased and longer times were allowed for dissociation of S-warfarin
from soluble HSA. It was also noted in Figure 4 that this effect was not significant when an
injection flow rate of 4.0 mL/min or higher was used on a 4.5 mm × 2.1 mm i.d. HSA
microcolumn. Similar results were obtained for R-warfarin. Based on this information, a flow
rate of at least 4.0 mL/min (i.e., an extraction time of 280 ms or less) was used in all further
free fraction determinations made in this report on 4.5 mm × 2.1 mm i.d. HSA microcolumns.
Table 1 shows some free fractions that were measured on these HSA microcolumns (prepared
by the Schiff base method) for R- and S-warfarin in the presence of excess soluble HSA. The
free fractions measured by ultrafiltraiton for the same samples are also provided. The results
obtained by ultrafast extraction in this case were acquired using a 4.5 mm × 2.1 mm i.d. HSA
J Chromatogr A. Author manuscript; available in PMC 2011 April 23.
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column operated at 4.5 mL/min (i.e., an extraction time of 250 ms). It was found under these
conditions that the free fractions measured for both R- and S-warfarin by ultrafiltration and
ultrafast extraction using HSA microcolumns were statistically identical, giving values that
agreed within 10% and ± 1 S.D. The precision of these two methods was also comparable, with
relative standard deviations of ±7–10% and ±15–16%, respectively, for the results in Table 1.
One potential advantage of using HSA microcolumns and ultrafast extraction for this type of
measurement is the ability of this approach to rapidly examine individual samples. For
example, in this study the time required for one sample injection at 4.5 mL/min on the 4.5 mm
× 2.1 mm i.d. HSA microcolumn was less than 1 min (i.e., 40 s in Figure 2). The total time
needed for single injections of a sample and standard was 1.5–2 min, and the time needed for
the triplicate analysis of both the sample and standard was 4–6 min. The total time needed for
comparable ultrafiltration studies in this report was 64 min for single measurements of the
sample and standard and 72 min for triplicate analyses of the sample and standard. This latter
period of time included both the ultrafiltration step and the time needed for sequential analysis
of samples and standards on an HPLC column. Besides being much faster, the HSA
microcolumn was also more convenient to use than ultrafiltration in free fraction measurements
because all operations on the sample were conducted in a single step. In contrast to this, the
ultrafiltration method required separate steps for the isolation of free drug fractions and for
their measurement.
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3.4 Extension of method to other drugs
The next stage of this research examined the use of HSA microcolumns with other drugs. Both
ibuprofen and imipramine were considered in this study because these drugs also have
relatively well-characterized binding to HSA (note: only the S-enantiomer of ibuprofen was
used in this current study for the sake of cost and because R- and S-ibuprofen have similar
affinities in their binding to HSA) [29]. Neither of these drugs has any appreciable fluorescence,
so one modification that was made in the method was the use of absorbance detection to monitor
the free drug fractions that were captured and later eluted from the HSA microcolumns. Shorter
HSA microcolumns with a higher relative level of active HSA were also used to provide good
retention while also allowing free fraction measurements to be made at more reasonable flow
rates that were utilized in the initial studies with R- and S-warfarin. This second modification
was made to allow higher resolution to be obtained between the non-retained and retained
peaks on the HSA microcolumns, thus making it easier to measure free fractions for drugs like
imipramine and ibuprofen that have weaker binding to HSA than warfarin [27–30].
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The affinity microcolumns used in this second round of studies were 2.0 or 3.0 mm long with
an inner diameter of 2.1 mm and contained HSA that had been immobilized by the SMCC
method. This immobilization scheme selectively couples HSA through its lone free cysteine
(Cys-34), an amino acid that is in a part of this protein that is distant from both of the major
drug binding sites. The result is a preparation of immobilized HSA that has a significant
improvement in its overall level of activity (i.e., an observed 1.6-fold increase) versus a general
amine-based coupling method such as the Schiff base method [40]. The higher relative activity
that this change in immobilization scheme provided made it possible to prepare shorter HSA
microcolumns without a significant loss in binding capacity, extraction efficiency or in the
level of retention that was seen on such columns. Under the sample conditions that were used
in this study, the amount of each drug that was applied to these small HSA microcolumns was
between 13% and 20% of the estimated column binding capacity, which still provided at least
a five-fold mol excess of HSA versus the drug that was applied in each sample.
Figure 5 shows some typical chromatograms obtained in free drug measurements when using
HSA microcolumns prepared by the SMCC method. The results shown here for S-warfarin and
imipramine where obtained on 2.5 mm × 2.1 mm i.d. HSA microcolumns at 2.0 mL/min and
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3.0 mL/min, respectively. Preliminary studies with warfarin, imipramine and ibuprofen
indicated that at least 95% of the free fractions of all these analytes were extracted by these
HSA microcolumns under such conditions. The smaller length of these columns versus those
used earlier in this study made it possible to use slightly lower flow rates and still obtain column
residence times for the sample of approximately 300 ms or less (i.e., 208–318 ms for the
examples shown in Figure 5; column residence times up to 350 ms were found to also be
effective in the analysis of S-ibuprofen). Although the use of flow rates in the range of 2.0 to
3.0 mL/min did increase the elution times needed for the retained drug fractions up to 120–
150 s for the most highly retained analytes (e.g., S-warfarin), retention times at higher flow
rates were similar to those in the work with HSA microcolumns prepared by using the Schiff
base (see Section 3.1–3.3). The free fractions measured for various mixtures of these drugs
with HSA are listed in Table 1. Good agreement was again seen between the results that were
measured with the HSA microcolumns that those that were determined by ultrafiltration. For
each drug that was tested, these values agreed within ± 1 S.D and had a relative difference of
only 6–10%.
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The smaller HSA microcolumns prepared by the SMCC method allowed for improved
resolution in the isolation of free drug fractions through at least two effects. First, the use of
shorter columns with a decreased void volume allowed for faster removal of the non-retained
protein and drug-protein complex. There was also an apparent increase in resolution for these
shorter affinity microcolumns at the lower flow rates at which they could be operated versus
the affinity microcolumns made earlier by the Schiff base method (e.g., see Figures 1 versus
5). The reason for this improvement in resolution is believed to be due to the relatively sharp
increase in plate height that occurs when working at high flow rates in this type of HSA column
[23,48,49], which results in part from the importance of stationary phase mass transfer within
such columns (e.g., see discussion in Section 3.2). As a result, the ability to use even slightly
lower flow rates for this particular analysis should have resulted in a smaller plate heights and
better column efficiency even through the overall column length had been reduced. Further
studies examining this effect are currently being performed, but the net result was that the
shorter and more active HSA microcolumns were easier to use in work with drugs that were
detected through absorbance measurements and that had lower affinities than R- or S-warfarin
for HSA.
3.5 Estimation of association equilibrium constants
HSA microcolumns were next tested for use in estimating the association equilibrium constant
(Ka) for a drug-protein interaction. This was accomplished by using the free fraction data
acquired on these columns along with the following equation that describes a drug and protein
interaction that involves 1:1 binding.
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(1)

Eq 1 is simply an expanded form of the equilibrium expression for the reaction of drug D with
protein P, in which [D-P] is the concentration of the drug-protein complex in the sample, Cd
is the total concentration of drug in the original sample (including both the free and proteinbound fractions), and Cp is the total concentration of protein in the sample. The value of [DP] in this case can be calculated from the measured free fraction (F) as shown below.
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(2)

Comparable equations can be derived for more complex drug-protein interactions.
Table 2 shows the Ka values determined for the various tested drugs with soluble HSA by using
eqs 1–2 and data acquired with the HSA microcolumns. These results again gave a good match
with values estimated from ultrafiltration data, with Ka values that differed by less than 15%
and overlapped within ± 1 S.D. In addition, the association equilibrium constants determined
for R- and S-warfarin using HSA microcolumns agreed within ± 2 S.D. and differed by only
9–35% versus literature values for a study that examined the interactions of R- and S-warfarin
with immobilized HSA at the same pH and temperature used in this current report [42].
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It was noted in the previous section how the use of ultrafast extraction and HSA microcolumns
was much faster than ultrafiltration for the determination of free drug fractions. This same
feature makes the use of HSA microcolumns a more rapid means for estimating association
equilibrium constants based on such data. The free drug measurements made here on HSA
microcolumns were also faster than the experiments conducted for R- and S-warfarin in Ref.
[42] using frontal analysis, in which 20–25 min were required per sample application. One
disadvantage of using HSA microcolumns for free fraction measurements is the precision is
not as high as it is when employing frontal analysis or a comparable technique (e.g., ±20–23%
for the Ka values in Table 2 determined using HSA microcolumns vs. ±3–10% for the literature
values).
The use of only a few data points to calculate an association equilibrium constant through free
fraction measurements ideally requires that the type of binding present is known in advance.
In this study, R- and S-warfarin were known to have a single high affinity site on HSA [42,
43]. If such information is not available, it should be kept in mind that the estimated Ka will
only be an apparent, weighted average that may reflect the contributions of multiple interactions
for a more complex system. This type of estimate may be acceptable for the high-throughput
screening of drug-protein binding [23,48,49], but a more detailed analysis will require
additional experiments and a wider range of drug or protein concentrations to examine the
desired interaction [17–19,21–23,42].
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The results for S-ibuprofen and imipramine in Table 2 can be used to illustrate this last concept.
For instance, S-ibuprofen has been noted to have two binding sites on HSA with similar
affinities (1.1 × 105 M−1 and 1.2 × 105 M−1 at 25 °C) [29]; in this situation, the results shown
in Table 2 for ultrafiltration and the HSA microcolumn screening method would give a
weighted average of these values. A slightly more complex situation occurs in the case of
imipramine, which has been shown to have a relatively high affinity site on HSA (Ka = 1.6 ×
105 M−1 at 37 °C) plus a large number of weaker binding regions (8–9 sites, average Ka = 1.5
× 103 M−1 at 37 °C). In this case, the use of a single-site model and the conditions employed
for imipramine and soluble HSA in Table 2 would be anticipated to give a value that is heavily
weighted towards the weaker affinity sites [30]. However, it is interesting to note that the elution
times seen on the HSA microcolumns for the retained, free fraction of imipramine (see Figure
5b) was consistent with a solute that has binding to HSA with an apparent Ka in the range of
105 M−1. This behavior was expected because the amount of injected, free imipramine was
much lower than the amount of HSA in the microcolumn, creating retention that mainly
reflected the binding of imipramine with its high affinity region on the immobilized HSA.
Thus, complementary information can be obtained on a drug interaction with HSA by
examining both the size of the retained free fraction and this fraction’s retention profile. This
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feature should be useful in future studies as a means for identifying drugs that do have more
than one type of interaction with HSA, especially if these interactions have significant
differences in their affinities.

4. Conclusion
It was found that ultrafast extraction based on HSA microcolumns can be used for measuring
the free fractions of some drugs in drug-protein mixtures. An advantage of this method is its
speed, which was approximately 40 s per injection at 4.5 mL/min in the case of R- and Swarfarin. This approach was adapted for use with other drugs and fluorescence or absorbance
detection. The free fractions measured by this method gave good agreement with those
determined by ultrafiltration, a common reference method for drug-protein binding studies.
Association equilibrium constants determined by this approach also agreed with ultrafiltration
and literature values. The availability of HSA and its low cost make this approach less
expensive to perform than ultrafast extraction based on columns containing immobilized
antibodies [35–37].
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It was found in this study that ultrafast affinity extraction with HSA microcolumns worked
well for drugs with relatively strong binding to HSA (i.e., Ka ~ 105 M−1 or greater, as occurs
for R/S-warfarin, S-ibuprofen and the high affinity site of imipramine on HSA) [42,43]. Further
work is now being conducted with computer simulations, other model analytes and additional
optimization to allow even lower affinity drugs to be examined by this technique. The
information in this report should also be useful in developing affinity microcolumns that
contain other proteins for drug-binding studies. In addition, the ability of these affinity
microcolumns to rapidly measure free fractions and to estimate association equilibrium
constants is expected to make this technique appealing for future use in the high-throughput
screening of drug candidates and in the study of drug-protein interactions [17,19,23,48,49].
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Figure 1.

General scheme for the separation of the free and protein-bound fractions of a drug in a sample
through the use of an affinity microcolumn that contains immobilized human serum albumin
(HSA).
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Figure 2.

Typical chromatograms obtained at 4.5 mL/min for 1.1 μL injections of (a) 10 μM R-warfarin
onto an HSA microcolumn, (b) 20.0 μM HSA plus 10.0 μM R-warfarin onto an HSA
microcolumn, or (c) 20.0 μM HSA plus 10.0 μM R-warfarin onto a control column. The HSA
microcolumn was prepared by the Schiff base method. The size of both this column and the
control column was 4.5 mm × 2.1 mm i.d. Other conditions are given in the text.
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Figure 3.

Simulated chromatograms for the binding and elution of samples containing R-warfarin on an
HSA microcolumn. The results in (a) show the predicted response for the injection of Rwarfarin or a mixture of R-warfarin and HSA onto an HSA microcolumn at 25 °C and pH 7.4
under the same sample, column, and flow rate conditions as were present for the experimental
results shown in Figure 2. The R-warfarin/HSA sample used in these simulations had 30% Rwarfarin in the free form, in line with experimental results presented later in this report.
Estimates of the activity for the original immobilized HSA (i.e., around 70–75%) were based
on previous data from the literature for similar columns [8,13]. The plots in (b) show how the
peak for the retained fraction of R-warfarin would be expected to change under these same
J Chromatogr A. Author manuscript; available in PMC 2011 April 23.
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conditions as the relative amount of active protein is decreased by 80%, 60% or 40% of its
initial value. Further details on the simulation model can be found in the Experimental section.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
J Chromatogr A. Author manuscript; available in PMC 2011 April 23.

Mallik et al.

Page 17

NIH-PA Author Manuscript
Figure 4.
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Effect of flow rate on the apparent free fractions measured for S-warfarin in samples containing
soluble HSA and injected onto an HSA microcolumn. These results were obtained for 1.1 μL
injections of a sample containing 20.0 μM HSA plus 8.5 μM S-warfarin. The HSA microcolumn
was prepared by the Schiff base method and had a size of 4.5 mm × 2.1 mm i.d. Other conditions
are given in the text.
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Figure 5.

Chromatograms obtained on 2.5 mm × 2.1 mm i.d. HSA microcolumns that had been prepared
by the SMCC method. The results shown in (a) were obtained at 2.0 mL/min for 20 μL samples
of 20.6 μM S-warfarin or 20.6 μM S-warfarin plus 25.0 μM HSA. The results shown in (b)
were obtained at 3.0 mL/min for 40.0 μM imipramine or 40.0 μM imipramine plus 45.0 μM
HSA. Other conditions are given in the text.
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Table 1

Free drug fractions measured for mixtures of various drugs with soluble HSA
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Measured free fractiona
HSA microcolumns (Ultrafast
extraction)

Ultrafiltration (Reference method)

S-Warfarin + HSA

0.20 (± 0.03)

0.20 (± 0.02)

R-Warfarin + HSA

0.31 (± 0.05)

0.28 (± 0.02)

S-Warfarin + HSA

0.23 (± 0.02)

0.21 (± 0.03)

S-Ibuprofen + HSA

0.28 (± 0.02)

0.25 (± 0.07)

Imipramine + HSA

0.92 (± 0.02)

0.86 (± 0.07)

Immobilization Method & Sample
Schiff Base Method

SMCC Method

a

These values were measured for the given samples at 25 °C in pH 7.4, 0.067 M potassium phosphate buffer. The numbers in parentheses represent
a range of ± 1 S.D. The sample concentrations and other conditions are given in Section 2.
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Table 2

Association equilibrium constants measured for various drugs with soluble HSA
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Immobilization Method & System
Studied

Apparent Association Equilibrium Constant, Ka (M−1)a
Ultrafast Extraction

Ultrafiltration

Literature Value

[Ref.]

R-Warfarin binding to HSA

1.7 (± 0.4) × 105

2.0 (± 0.3) × 105

2.6 (± 0.1) × 105

[28]

S-Warfarin binding to HSA

105

105

105

[28]

Schiff base Method

3.1 (± 0.6) ×

3.1 (± 0.4) ×

3.4 (± 0.1) ×

SMCC Method
S-Warfarin binding to HSAa

3.4 (± 0.5) × 105

4.1 (± 0.7) × 105

3.4 (± 0.1) × 105

[28]

S-Ibuprofen binding to HSAb

1.6 (± 0.3) × 105

2.0 (± 0.4) × 105

1.1–1.2 × 105

[29]

103

103

103

[40]

Imipramine binding to HSA

2.1 (± 0.3) ×

4.1 (± 0.2) ×

1.8 ×

a
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The numbers in parentheses represent a range of ± 1 S.D. The listed values were measured at 25 °C and, except where indicated otherwise, in the
presence of pH 7.4 phosphate buffer or phosphate-buffered saline. The value from Ref. [29] was measured at pH 6.9 and is the average of two similar
binding sites for S-ibuprofen on HSA; the value from Ref. [40] is also a weighted average for two sets of binding sites, as obtained under conditions
similar to those used in this report [30]. The values given for the HSA microcolumns and ultrafiltration are for soluble HSA. The values from Refs.
[28] and [29] were obtained with immobilized HSA. The value from Ref. [40] was obtained using soluble HSA. The sample concentrations and
conditions used in this current study are provided in Section 2.
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